ReNeuron Group plc Webcast of Preliminary Results (5240C)
June 18 2019 - 1:00AM
UK Regulatory
TIDMRENE
RNS Number : 5240C
ReNeuron Group plc
18 June 2019
18 June 2019 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Webcast of Preliminary Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, will webcast the analyst
briefing on the day of its preliminary results, Thursday 11 July
2019.
To listen to the webcast live, please log on to the following
web address approximately 5 minutes before 10.00am BST on the day
of results:
https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
A recording of the webcast will later be made available at
ReNeuron's website, www.reneuron.com.
The analyst briefing will be held at 10.00am BST on 11 July 2019
at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, please contact Buchanan on
reneuron@buchanan.uk.com or 020 7466 5000.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US) +1 212 600 1902
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis
pigmentosa, and for disability as a result of stroke. ReNeuron is
also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGUWCQUPBGAM
(END) Dow Jones Newswires
June 18, 2019 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024